Author

Edouard Louis

New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)
New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)

Edouard Louis  et al.

FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS
FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

Edouard Louis  et al.

RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY
RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Edouard Louis  et al.

Can Flexible Treatment Administration Impact Outcomes in Inflammatory Bowel Disease? (Takeda Pharmaceuticals International AG)
Can Flexible Treatment Administration Impact Outcomes in Inflammatory Bowel Disease? (Takeda Pharmaceuticals International AG)

Edouard Louis  et al.

Exit strategies: Still to be considered?
Exit strategies: Still to be considered?

Edouard Louis

FUTURE IBD: The emerging role of the IL-23 inhibitor class in Crohn’s disease (AbbVie)
FUTURE IBD: The emerging role of the IL-23 inhibitor class in Crohn’s disease (AbbVie)

Edouard Louis  et al.

COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE
COMPARISON OF CLINICAL IMPROVEMENT AS MEASURED BY TWO QUALITY-OF-LIFE INDEXES: A POOLED ANALYSIS OF VEDOLIZUMAB RANDOMIZED CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE

Edouard Louis  et al.

USE OF FAECAL CALPROTECTIN AS A PROGNOSTIC MARKER OF RESPONSE TO TREATMENT WITH FILGOTINIB: POST HOC ANALYSIS FROM THE SELECTION STUDY
USE OF FAECAL CALPROTECTIN AS A PROGNOSTIC MARKER OF RESPONSE TO TREATMENT WITH FILGOTINIB: POST HOC ANALYSIS FROM THE SELECTION STUDY

Edouard Louis  et al.

Proteomics signatures in IBD: Now is the time
Proteomics signatures in IBD: Now is the time

Edouard Louis

PATTERNS OF CORTICOSTEROID EXPOSURE AND EXCESS IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE DETERMINANTS, INCIDENCE AND CONSEQUENCES OF CORTICOSTEROID EXCESS (DICE) ONLINE MONITORING TOOL
PATTERNS OF CORTICOSTEROID EXPOSURE AND EXCESS IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE DETERMINANTS, INCIDENCE AND CONSEQUENCES OF CORTICOSTEROID EXCESS (DICE) ONLINE MONITORING TOOL

Edouard Louis  et al.

EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS
EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS

Edouard Louis  et al.

EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE
EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE

Edouard Louis  et al.

VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS
VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS

Edouard Louis  et al.

COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY
COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Edouard Louis  et al.

PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE SELECTION STUDY
PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE SELECTION STUDY

Edouard Louis  et al.

EFFECTS OF AN EXCLUSION DIET ON INFLAMMATION MARKERS AND MAINTENANCE OF REMISSION IN PATIENTS WITH QUIESCENT IBD – A 1-YEAR PROSPECTIVE TRIAL
EFFECTS OF AN EXCLUSION DIET ON INFLAMMATION MARKERS AND MAINTENANCE OF REMISSION IN PATIENTS WITH QUIESCENT IBD – A 1-YEAR PROSPECTIVE TRIAL

Edouard Louis  et al.

OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE
OPTIMIZING THE POSITION OF VEDOLIZUMAB IN TREATMENT SEQUENCES FOR CROHN’S DISEASE: RESULTS FROM A MARKOV MODEL SIMULATION USING REAL-WORLD EVIDENCE

Edouard Louis  et al.

EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY
EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Edouard Louis  et al.

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Edouard Louis  et al.

COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE
COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE

Edouard Louis  et al.

Item 1 - 20 / 24
1
2